|
US7291615B2
(en)
|
2003-05-01 |
2007-11-06 |
Bristol-Myers Squibb Company |
Cyclic derivatives as modulators of chemokine receptor activity
|
|
CN1933847A
(zh)
*
|
2004-01-16 |
2007-03-21 |
密歇根大学董事会 |
Smac肽模拟物及其应用
|
|
EP1713542A2
(en)
*
|
2004-02-05 |
2006-10-25 |
Novartis AG |
COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR
|
|
US7345081B2
(en)
|
2004-03-23 |
2008-03-18 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
|
PL2253614T3
(pl)
*
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitory IAP
|
|
KR100926203B1
(ko)
|
2004-07-02 |
2009-11-09 |
제넨테크, 인크. |
Iap의 억제제
|
|
JP5230865B2
(ja)
|
2004-07-15 |
2013-07-10 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap結合性化合物
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
EA012810B1
(ru)
|
2005-02-25 |
2009-12-30 |
Тетралоджик Фармасеутикалс |
Димерные ингибиторы ингибиторов белков апоптоза (iap)
|
|
DE102005017116A1
(de)
|
2005-04-13 |
2006-10-26 |
Novartis Ag |
Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
|
|
WO2006122408A1
(en)
|
2005-05-18 |
2006-11-23 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
US8318717B2
(en)
|
2005-05-25 |
2012-11-27 |
2Curex |
Compounds modifying apoptosis
|
|
WO2006128455A2
(en)
|
2005-05-25 |
2006-12-07 |
2Curex Aps |
Compounds modifying apoptosis
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
AU2006308453B9
(en)
|
2005-10-25 |
2011-12-01 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
WO2007106192A2
(en)
*
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
US20090005411A1
(en)
*
|
2005-12-20 |
2009-01-01 |
Novartic Ag |
Combinations of Organic Compounds
|
|
US7622496B2
(en)
*
|
2005-12-23 |
2009-11-24 |
Zealand Pharma A/S |
Modified lysine-mimetic compounds
|
|
TWI504597B
(zh)
*
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
|
|
BRPI0711591A2
(pt)
|
2006-05-16 |
2011-11-16 |
Aegera Therapeutics, Inc. |
composto de ligação de domìnio bir da iap
|
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
JP5452223B2
(ja)
*
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap阻害剤
|
|
MX2009000824A
(es)
|
2006-07-24 |
2009-02-04 |
Tetralogic Pharmaceuticals Cor |
Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
AU2007307763A1
(en)
|
2006-10-12 |
2008-04-17 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
KR20090087094A
(ko)
|
2006-11-28 |
2009-08-14 |
노파르티스 아게 |
Iap 억제제 및 flt3 억제제의 조합물
|
|
CN101605786A
(zh)
*
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
ES2558856T3
(es)
|
2006-12-21 |
2016-02-09 |
Zealand Pharma A/S |
Síntesis de compuestos de pirrolidina
|
|
CA2684169C
(en)
*
|
2007-04-12 |
2012-06-19 |
Joyant Pharmaceuticals, Inc. |
Smac mimetic dimers and trimers useful as anti-cancer agents
|
|
NZ598890A
(en)
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
|
|
DK2240506T3
(da)
*
|
2008-01-11 |
2013-04-08 |
Genentech Inc |
IAP inhibitorer
|
|
US8835393B2
(en)
|
2008-08-02 |
2014-09-16 |
Genentech, Inc. |
Inhibitors of IAP
|
|
JP2012500272A
(ja)
*
|
2008-08-16 |
2012-01-05 |
ジェネンテック, インコーポレイテッド |
Iapのアザインドールインヒビター
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
UY32826A
(es)
|
2009-08-04 |
2011-02-28 |
Takeda Pharmaceutical |
Compuestos heterocíclicos
|
|
MX351274B
(es)
|
2009-08-12 |
2017-10-06 |
Novartis Ag |
Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
|
|
JP2013505446A
(ja)
*
|
2009-09-18 |
2013-02-14 |
ノバルティス アーゲー |
Iap阻害剤化合物のためのバイオマーカー
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
US8859541B2
(en)
*
|
2012-02-27 |
2014-10-14 |
Boehringer Ingelheim International Gmbh |
6-alkynylpyridines
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
CA2988436A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
ES2870106T3
(es)
|
2017-05-05 |
2021-10-26 |
Zealand Pharma As |
Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
|
|
CN110944719A
(zh)
*
|
2017-07-25 |
2020-03-31 |
合帕吉恩治疗公司 |
凋亡蛋白的二聚肽抑制剂
|
|
WO2019021289A1
(en)
|
2017-07-27 |
2019-01-31 |
The National Institute for Biotechnology in the Negev Ltd. |
SMAC / DIABLO INHIBITORS USEFUL IN THE TREATMENT OF CANCER
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
WO2025256500A1
(zh)
*
|
2024-06-11 |
2025-12-18 |
温州玮祎康泽生物科技有限公司 |
Xiap e3连接酶作为肿瘤治疗靶点及其靶向化合物的应用
|